Navigation Links
Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients
Date:10/2/2008

GOTEBORG, Sweden, October 2 /PRNewswire/ -- Calabar AB announced today that their Phase II repeated dose study in xerostomia ("dry mouth") patients has been initiated. Specifically, the drug will be studied in 45 dry mouth patients between the ages of 20 to 75. The objective of the study is to select a dose for evaluation in a succeeding Phase III efficacy study.

Xalieve(TM) is a gel containing the cholinesterase inhibitor physostigmine. It is administered locally in the mouth where physostigmine diffuses through the mucosa reaching the minor glands. By inhibiting cholinesterase, acetylcholine accumulates and the elevated concentrations stimulate the muscarinic receptors in the minor glands, improving saliva production. Unlike systemically administered drugs, the local route of administration limits adverse events.

"Xalieve(TM) offers a completely new approach in treating dry mouth and we are very excited about this Phase II study," said Mr. Fredrik Rook, VP Business Development of Calabar. "Xerostomia is not getting the attention it deserves. These patients are experiencing dramatic decrease in quality of life, such as difficulty in swallowing and speaking, and a burning sensation in the mouth. Xalieve(TM) has the possibility to radically improve the life of millions of people suffering from dry mouth."

About Calabar AB:

Calabar is a privately-held company committed to developing pharmaceutical products addressing the significant unmet needs of xerostomia "dry mouth". The company's product Xalieve(TM) is a locally administered formulation of the cholinesterase inhibitor physostigmine, which has been shown to effectively increase salivary flow. The company is part of the Karolinska Development AB portfolio. For more information, please visit http://www.calabar.se

Contact:

VP Business Development,

Fredrik Rook,

+46-8-524-860-38,


SOURCE Calabar AB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
2. Study Demonstrates That AHCC(R) Provides Immune Enhancement Against the West Nile Virus
3. Karolinska Institutet to Test Vicals Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
4. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
5. Two New Alzheimers Disease Studies Show Advances Against Different Treatment Targets
6. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
7. Novel Approach May Protect Against Heart Attack Injury
8. Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement With Johns Hopkins University
9. Grocery Manufacturers Association: Study Signals Progress in Battle Against Obesity
10. Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains
11. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation (the "Company") ... has received commitments from institutional investors to purchase an ... stock in an at-the-market registered direct offering, led by ... entered into definitive purchase agreements with these investors pursuant ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: BRDT), ... distributor of highly sophisticated agro-breeding solutions for plant breeders ... the Company,s board of directors appointed chemistry and pharmaceutical ... new member of the board. From 1975 ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... --   Masimo (NASDAQ: MASI ... Acoustic Monitoring™, and Masimo SET ® Measure-Through Motion ... Medical Devices, Inc. dismissed all outstanding claims against Masimo ... and Cercacor.   Masimo did not incur any liability to ...
... QBC Diagnostics, a global manufacturer of hematology ... the company has been awarded a U.S. General ... Equipment and Services. GSA,s Scientific Equipment ... with scientific instruments for a wide variety of ...
Cached Medicine Technology:Essential Medical Dismisses Patent Case against Masimo and Cercacor 2Essential Medical Dismisses Patent Case against Masimo and Cercacor 3Essential Medical Dismisses Patent Case against Masimo and Cercacor 4QBC Diagnostics Awarded GSA Contract 2
(Date:4/17/2014)... pain relief targets that could be used to ... King,s College London made the discovery when researching ... of the body. , Dr Marzia Malcangio said: ... pain generation and our findings could help chemotherapy ... One potential side effect of some chemotherapy drugs ...
(Date:4/17/2014)... Diego School of Medicine report that older women, plucky ... loss are more likely to be compassionate toward strangers ... in this month,s issue of the International Journal ... associated with better health and well-being as we age, ... the outcomes of individuals whose deficits in compassion put ...
(Date:4/17/2014)... has created a new technology for modifying human ... the body and selectively target cancer and other ... that monitor and modify human physiology is a ... existing technology enabled bioengineers to build such devices ... in a customized fashion. , "The project addressed ...
(Date:4/17/2014)... NEW YORK, NY (April 16, 2014) The cause ... but a new study proposes that neurons may be ... own immune system, similar to the way autoimmune diseases ... attack the body,s cells. The study was published April ... is a new, and likely controversial, idea in Parkinson,s ...
(Date:4/17/2014)... 2014 EcoHealth Alliance, a nonprofit organization that focuses ... comprehensive review today examining the current state of knowledge ... calls for improved global surveillance strategies to combat the ... of Ebola in West Africa that has claimed the ... and Liberia. According to the World Health Organization ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3
... national provider of tele-health solutions, has received full accreditation from URAC ... URAC assures that SironaHealth has met all relevant standards and performs ... is timely, confidential, and includes medically appropriate care and treatment advice. ... ...
... complete medical travel packages for North American patients seeking ... ... Long Beach, Calif. (PRWEB) April 8, 2009 -- With U.S. ... trillion this year, health insurers, self-insured employers, groups and individuals are ...
... Multiple, anatomically distinct lung cancer tumors may frequently arise ... analysis of patient tumor samples published in the April ... National Cancer Institute. , Some lung cancer patients ... diagnosis. Although such multiple tumors usually share a common ...
... that the growth factor known as TGF-β is essential to ... blocking it can cause retinal dysfunction. These findings, published in ... have an important impact on the prevention and treatment of ... results are significant because they add to our understanding of ...
... testing after ,very promising, early results, , , TUESDAY, April ... radically different way of attacking prostate cancer has done ... larger-scale testing, researchers report. , One standard treatment for ... male hormones such as testosterone that help drive tumor ...
... women, not men, researchers report , , TUESDAY, April 7 ... the list of cardiac problems linked to overweight and ... however we measure it, is associated with the risk ... fellow at the Cardiovascular Epidemiology Research Unit of Beth ...
Cached Medicine News:Health News:SironaHealth Receives URAC Accreditation as a Health Call Center 2Health News:SironaHealth Receives URAC Accreditation as a Health Call Center 3Health News:Reducing Costs, Not Care: Medical Travel to New Zealand Can Help Alleviate Rising U.S. Healthcare Expenses for Insurers and Self-funded Employers 2Health News:Reducing Costs, Not Care: Medical Travel to New Zealand Can Help Alleviate Rising U.S. Healthcare Expenses for Insurers and Self-funded Employers 3Health News:Reducing Costs, Not Care: Medical Travel to New Zealand Can Help Alleviate Rising U.S. Healthcare Expenses for Insurers and Self-funded Employers 4Health News:Multifocal lung cancers appear to originate from single cancer clone 2Health News:Growth factor TGF-B helps maintain health of retinal blood vessels 2Health News:New Prostate Cancer Drug May Hold Promise 2Health News:New Prostate Cancer Drug May Hold Promise 3Health News:Obesity Linked to Heart Failure Risk 2
... unique DHEA-S-7kits feature a ... against the C-7 position ... with no cross-reactivity with ... RIA has been optimized ...
... based on the competition principle and the ... present in the sample and a fixed ... compete for the binding sites of a ... After one hour incubation the microtiterplate is ...
Inquire...
... It is a compact Latex based reagent kit ... well as to determine the level of RF ... patient sera. The kit includes antigen coated fine ... control sera in plastic squeezable dropping bottles, re-usable ...
Medicine Products: